New Study Links Semaglutide (Wegovy and Ozempic) to Elevated Risk of Severe Eye Condition NAION
Research from Mass Eye and Ear reveals a significant increase in the risk of NAION among Semaglutide users.
Initially Published in Integrated Healthcare
Semaglutide, under Wegovy and Ozempic brands, has gained popularity in recent years, given its weight loss effect. Parallel to this trend are related concerns in their safety profile. One of these concerns has been highlighted by the recent study led by Mass Eye and Ear resea…
Keep reading with a 7-day free trial
Subscribe to Integrated Healthcare to keep reading this post and get 7 days of free access to the full post archives.